Byakangelicin, a main furanocoumarin constituent isolated and characterized as an aldose reductase inhibitor from the roots of Angelica dahurica, is an aldose reductase inhibitor and induces cytochrome P450 3A4 expression via transactivation of pregnane X receptors in human hepatocytes.

Product information

CAS Number: 482-25-7

Molecular Weight: 334.32

Formula: C17H18O7

Chemical Name: 7H-Furo(3,2-g)(1)benzopyran-7-one, 9-(2,3-dihydroxy-3-methylbutoxy)-4-methoxy-, (R)-

Smiles: COC1C2C=COC=2C(OC[C@@H](O)C(C)(C)O)=C2OC(=O)C=CC2=1

InChiKey: PKRPFNXROFUNDE-LLVKDONJSA-N

InChi: InChI=1S/C17H18O7/c1-17(2,20)11(18)8-23-16-14-10(6-7-22-14)13(21-3)9-4-5-12(19)24-15(9)16/h4-7,11,18,20H,8H2,1-3H3/t11-/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

References:

1. Kang YY, et al. Byakangelicin as a modulator for improved distribution and bioactivity of natural compounds and synthetic drugs in the brain. Phytomedicine. 2019 May 17;62:152963.
2. Yang J, et al. Byakangelicin induces cytochrome P450 3A4 expression via transactivation of pregnane X receptors in human hepatocytes. Br J Pharmacol. 2011 Jan;162(2):441-51.

Products are for research use only. Not for human use.